HIV Infections Clinical Trial
Official title:
Community Partnerships to Prevent Urban Youth Health Risks (CHAMPions)
This study will examine methods for involving local community members in programs to teach urban youth about how to prevent transmission of HIV.
HIV is a sexually transmitted virus that damages or destroys a body's immune system. When
the infection progresses to its later stages, AIDS can develop. Several programs have been
developed for educating adolescents about how to prevent HIV transmission. Preventing
infection is particularly important because there is not yet a way to cure HIV. This study
will examine the processes needed to train community members to deliver HIV prevention
programs to urban youth.
This study has three steps. In Step 1, an existing group of urban community members who have
already delivered the Be Proud! Be Responsible! HIV prevention program will be invited to
serve as mentors for new HIV educators in the community. Participants in this step will
complete self-administered assessments of their willingness to collaborate with
university-based researchers, their confidence in skills necessary for collaborative
projects, and any foreseeable obstacles to participation. The goal of this step is to
examine the response over time to ongoing HIV leadership.
In Step 2, parents from the targeted community will be recruited and trained in HIV
prevention programs. They will be randomly assigned to one of three programs: Becoming a
Responsible Teen, Be Proud! Be Responsible!, and Reducing the Risk. All three of these
programs involve group meetings with adolescents to discuss puberty, sexuality,
communication, self-esteem, HIV/AIDS, and setting and achieving goals and dreams.
Participants in this phase will undergo the same assessments as those in Step 1.
In Step 3, the parents trained in Step 2 will be randomly assigned to a middle school or
high school where they will deliver the program in which they were trained. Randomly
selected adolescent participants from these schools will be assigned to whichever program is
being offered at their school. All three prevention programs will include four to six
sessions over 4 to 6 weeks. Adolescent participants will be required to complete interviews
and questionnaires when they enter the study, after 3 months, and after 15 months. These
interviews and questionnaires will measure HIV/AIDS knowledge, self-esteem, intention to
protect health, and engagement in risk-taking behaviors. Parent participants in Step 3 will
repeat the assessments from Steps 1 and 2 before and after delivering their prevention
curriculums.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |